Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Novavax is set to release its quarterly earnings on May 9, 2025, with analysts expecting earnings per share of $0.19 and projected revenue of $204.1 million. The company’s recent multi-billion-dollar ...

Explore Novavax's Q1 2025 earnings insights, highlighting raised revenue forecasts, strategic partnerships, and progress toward non-GAAP profitability ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...